This research demonstrates enhanced relaxivity in MRI using a hybrid nanogel, indicating potential for improved tumor theranostics.
Bridging tumor diagnosis and therapy remains a major challenge, largely due to the clinical separation of imaging and treatment, compounded by the low relaxivity of conventional MRI contrast agents. To address these limitations, we developed a copper-manganese hybrid nanogel (CMNG) via the in situ incorporation of Mn2+ ions and CuS nanoparticles within a cross-linked polymeric network. This multifunctional design enables T1-weighted MRI-guided photothermal-chemodynamic therapy. The nanogel matrix significantly enhances the relaxivity of paramagnetic Mn2+ ions (r1 = 10.81 mM-1 s-1), surpassing that of clinically approved Gd-based agents. Under 808 nm laser irradiation, CMNG exhibits efficient photothermal conversion (η = 23.29%), which synergistically enhances Cu+/Mn2+-mediated Fenton-like reactions, resulting in elevated hydroxyl radical (˙OH) production for effective tumor ablation and inhibition of tumor progression. This work presents a rational materials design strategy for integrated theranostic platforms. By combining MRI-guided tracking with potent therapeutic efficacy, the CMNG system offers a promising paradigm for precision cancer theranostics.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: